Navigation Links
CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus

HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that it has successfully completed an important pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study clearly demonstrated a robust protective effect in mice treated with the Company's synDNA(TM) vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus (Vietnam/1203/04). The lethal challenge testing was conducted by recognized collaborators in the field under a sponsored research agreement with the Company.

The complete results from this study and related tests of synDNA(TM) vaccines will be presented at the 2007 DNA Vaccine conference to be held 23-25 May 2007 in Malaga, Spain.

Dr. Yin Chen, Chief Scientific Officer, stated, "This novel DNA vaccine was produced using a unique combination of novel gene sequences and our proprietary synDNA(TM) production technology. We are extremely excited about this initial robust response in an animal challenge model."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release ar
'"/>




Page: 1 2

Related medicine technology :

1. CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE ... Nutraceuticals Industry Outlook to 2017 - Increasing Demand ... comprehensive analysis of the industry past, present and ... Canada market with outlook ... and dietary supplements. Additionally the sub-segments of the ...
(Date:9/30/2014)... , September 30, 2014 ... Inc. (NASDAQ: IMMU ), Aeterna Zentaris Inc. ... OPK ), Navidea Biopharmaceuticals Inc. (NYSE MKT: ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,505.85, down 0.14%, the ...
(Date:9/30/2014)... N.C. , Sept. 30, 2014 ... Viztek LLC (Viztek), a leading provider of complete ... HeartIT,s zero footprint patent portfolio. The licensed patents ... provide access to diagnostic-quality medical images in a ... of the agreement, Viztek and its Subsidiaries will ...
Breaking Medicine Technology:North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5
... RALEIGH, N.C., June 7, 2011 BioDelivery Sciences International, ... Mark A. Sirgo, President and Chief Executive Officer of ... at the Grand Hyatt, New York City.  The presentation ... Eastern Time.   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
... Healthmark Industries was honored with two award wins ... Service Personnel (MSHCSP). At last week,s annual ... the Lifetime Honorary Achievement Award for his service to ... The same night Healthmark was also awarded the "Robert ...
Cached Medicine Technology:BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 2BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 3
(Date:9/30/2014)... and its partners successfully established a visual mapping ... myeloid derived suppressor cells (MDSC). The damage and ... understood, however this is a major stepping stone ... by tumor-derived factors from precursors present in hematopoietic ... spleen. This population of cells suppresses the activity ...
(Date:9/30/2014)... for a genetic condition would cut their risk of ... found. , In a major study, Dr Ian Frayling ... the University of Exeter,s Medical School assessed the effectiveness ... condition known as Lynch Syndrome. ... genes which check the spelling in DNA. The condition ...
(Date:9/30/2014)... people who are diagnosed with bowel cancer would be ... them and their relatives, new research has concluded. ... were funded by the National Institute for Health Research ... effectiveness and cost-effectiveness of screening for Lynch Syndrome. Their ... that screening the 1,700 people under the age of ...
(Date:9/30/2014)... 2014 This two-day, advanced PT ... sequellae that may arise following a concussion or ... can be varied, from sports related injuries, car accidents, ... by the thousands of returning soldiers from war zone ... and blunt traumas can result in similar injuries, the ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, ... given broad-spectrum antibiotics before the age of 2 may ... childhood, new research suggests. Broad-spectrum antibiotics target a ... the study. "It is a reason to think ... are picking," said lead researcher Dr. Charles Bailey, attending ...
Breaking Medicine News(10 mins):Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3Health News:Genetic test for cancer patients could be cost-effective and prevent further cases 2Health News:Genetic test for cancer patients could be cost-effective and prevent further cases 3Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3
... BEACH, Calif., May 1 With the world gripped by ... epidemic, how can people be adequately prepared for the dangers ... Newport Beach psychologist, says, "People need to be informed, prepared, ... in this moment." People are obsessing over the swine ...
... HULL, England, May 1 Smith & Nephew,s Advanced Wound Management ... Patents Court, in the High Court of Justice of England and ... asserted against Smith & Nephew of the Negative Pressure Wound Therapy ... (KCI) (NYSE: KCI ). The 3 other claims ...
... The Quigley Corporation, (Nasdaq: QGLY ) ... of $4.0 million, for the first quarter ended March 31, 2009, ... decrease in net sales for the first quarter of 2009 reflects ... reported by Information Resources Inc., ("IRI") data, general economic weakness and ...
... 1 Gaiam, Inc. (Nasdaq: GAIA ), ... products and services to customers who value personal development, ... announce results for the first quarter ended March 31, ... 6, 2009. The Company will hold a teleconference to ...
... to $2.70 - $2.85 per Diluted ShareVIRGINIA BEACH, Va., May 1, ... that its net income for the first quarter of 2009 increased ... income of $33.6 million, or $0.62 per diluted share, for the ... , ...
... fitness, and performance services, recently supported Global Medical Brigades on a ... ... Brook, IL (PRWeb) May 1, 2009-- AthletiCo , an Illinois-based ... Medical Brigades on a medical mission trip to Honduras. ...
Cached Medicine News:Health News:How to Be Prepared for, but Not Paralyzed by Fear of, the Swine Flu Epidemic 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 2Health News:The Quigley Corporation Reports First Quarter 2009 Results 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 4Health News:The Quigley Corporation Reports First Quarter 2009 Results 5Health News:The Quigley Corporation Reports First Quarter 2009 Results 6Health News:The Quigley Corporation Reports First Quarter 2009 Results 7Health News:The Quigley Corporation Reports First Quarter 2009 Results 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 2Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 3Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 4Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 5Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 6Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 7Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 9Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 10Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 11Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 12Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 13Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 14Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 15Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 16Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 17Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 18Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 2Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 3
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: